Cognition Therapeutics (CGTX) to Post Quarterly Earnings on ThursdayMarket Beat·7 hours agoCGTX+1.48%
The Fringes of Wall Street: How Small-Cap Innovators and Niche Bets Are Navigating 2026Global Report·8 hours agoCERT-3.15%BLNK+4.68%
US Equities Tracker: Restructuring and Pipeline Milestones Shape H2 2026Global Report·Jul 22 at 04:18 AMSFM+13.95%CGTX+1.48%
The Unbundling of the Long Tail: Structural Realities at the Edges of the Value ChainGlobal Report·Jul 21 at 04:13 AMNUE+0.61%BTG+1.55%
Cognition Therapeutics posts press release on B. Riley summit fireside chat to IR websitePUBT·Jul 13 at 06:31 AMCGTX+1.48%
Hippo deploys Cognition’s Devin AI software engineer across insurance operationsPUBT·Jun 25 at 08:02 AMHIPO+13.16%CGTX+1.48%
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga_article·Jun 24 at 12:05 PMATLN0.00%PLSM-2.64%
Cognition Therapeutics targets mid-2027 start for Phase 3 zervimesine trial in DLB psychosisPUBT·Jun 24 at 06:30 AMCGTX+1.48%
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes | CGTX Stock NewsStockTitan·Jun 23 at 10:30 PMCGTX+1.48%
Cognition Therapeutics shareholders elect Aaron Fletcher, Lisa Ricciardi as Class II directorsPUBT·Jun 18 at 07:06 AMCGTX+1.48%
World Wide Technology Launches ‘Defending at the Speed of AI’ Initiative with Horizon3.ai, Empirical Security, Infoblox, and CognitionUnusual Whales·Jun 16 at 09:07 AMCGTX+1.48%
